Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer.
We present pretreatment Ga prostate-specific membrane antigen (PSMA) PET/CT and posttreatment Lu-PSMA whole-body scintigraphy images of a 60-year-old patient with metastatic prostate cancer who is dramatically responding to Lu-PSMA treatment.
From the Departments of *Nuclear Medicine and †Radiation Oncology, Ankara University Medical Faculty, Ankara, Turkey.
Cigdem
C
Soydal
Elgin
E
Ozkan
Serap
S
Akyurek
Nuriye Ozlem
NO
Kucuk
D004492:Edetic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D006801:Humans; D008187:Lutetium / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis; D009842:Oligopeptides / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging / Q000473:pathology / Q000532:radiotherapy*; D019275:Radiopharmaceuticals / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed
D005709:Gallium Isotopes; D005710:Gallium Radioisotopes; D009842:Oligopeptides; D019275:Radiopharmaceuticals; C000718244:gallium 68 PSMA-11; D008187:Lutetium; D004492:Edetic Acid